Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Grifols S.A. (GRFS)

Grifols S.A. (GRFS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Should Value Investors Consider Grifols (GRFS) Stock Now?

Let's see if Grifols (GRFS) stock is a good choice for value-oriented investors right now from multiple angles.

GRFS : 18.53 (-0.86%)
Report [2019-2026], Cell Surface Markers Market Size, Share, Growth, Trends, Revenue, Analysis, Competitive Landscape, Forecast

The rising investments for effective medicines is predicted to drive the global Cell Surface Markers Market during the forecast period, states Fortune Business Insights in a report. The growing cognizance...

ABCZY : 19.4000 (+2.75%)
GRFS : 18.53 (-0.86%)
The Dow Jones Sustainability Index recognizes Grifols as one of the world's most sustainable companies

, /PRNewswire/ -- Grifols (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS), a global healthcare company and one of the world's leading producers of plasma-derived medicines with more than 100 years of history contributing...

GRF : 7.65 (-0.65%)
GRFS : 18.53 (-0.86%)
Grifols partners with TRC Healthcare to streamline intravenous compounding education

, /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived therapies and provider of technologies and services for hospitals, clinics and compounding...

GRF : 7.65 (-0.65%)
GRFS : 18.53 (-0.86%)
Forget Bargain Hunting: Play 5 Stocks With Rising P/E

Bet on these top-ranked stocks with rising P/E to realize outsized gains.

CI : 209.14 (-1.58%)
DRRX : 1.8500 (+1.65%)
GRFS : 18.53 (-0.86%)
PTI : 1.0600 (-2.75%)
CWBR : 1.3500 (+1.50%)
GRFS vs. ZTS: Which Stock Is the Better Value Option?

GRFS vs. ZTS: Which Stock Is the Better Value Option?

GRFS : 18.53 (-0.86%)
ZTS : 160.38 (-0.68%)
Thinking about buying stock in Staffing 360 Solutions, Electrameccanica Vehicles, Grifols SA, Newage Beverage, or Norwegian Cruise Line?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for STAF, SOLO, GRFS, NBEV, and NCLH.

GRFS : 18.53 (-0.86%)
NCLH : 22.87 (-3.42%)
STAF : 1.1100 (-5.13%)
Grifols' anti-SARS-CoV-2 hyperimmune globulin begins clinical trial in patients with COVID-19

, /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of therapies with plasma-derived proteins with a track record of more than 100 years dedicated to enhancing...

GRF : 7.65 (-0.65%)
GRFS : 18.53 (-0.86%)
Grifols closes the acquisition of Green Cross fractionation plant in Canada and 11 plasma centers in the U.S.

- - - - , /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and one of world's leading producers of plasma-derived medicines, today announced the closing...

GRF : 7.65 (-0.65%)
GRFS : 18.53 (-0.86%)
Grifols to acquire Alkahest to enhance discovery research and development to identify innovative therapies for age-related diseases based upon an understanding of the human plasma proteome

, and , /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, today announced...

GRF : 7.65 (-0.65%)
GRFS : 18.53 (-0.86%)
Grifols starts production of its hyperimmune immunoglobulin as a potential passive immune therapy against COVID-19

, /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of therapies with plasma-derived proteins with a track record of more than 100 years dedicated to enhancing...

GRF : 7.65 (-0.65%)
GRFS : 18.53 (-0.86%)
Racing Against Time, Medical Researchers, Life Science Companies and COVID-19 Survivors Launch National Campaign to Drive Blood Plasma Donation

and , /PRNewswire/ -- A coalition of world-leading medical and research institutions, blood centers, life science companies, technology companies, philanthropic organizations, and COVID-19 survivor...

MSFT : 214.07 (-0.54%)
GRF : 7.65 (-0.65%)
GRFS : 18.53 (-0.86%)
Grifols Procleix Panther System with Automation Ready Technology (ART) receives FDA Approval

, /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P and NASDAQ: GRFS), a leading global producer of plasma-derived medicines and a leader in the development of innovative diagnostic solutions, today announced...

GRF : 7.65 (-0.65%)
GRFS : 18.53 (-0.86%)
Grifols launches new 3-mL (900-IU) vial for high-potency HyperRAB® (rabies immune globulin [human])

Grifols (MCE:GRF, MCE:GRF.P NASDAQ:GRFS), a leading global producer of plasma-derived medicines, today announced the launch of a new 3-mL (900-IU) vial for HyperRAB (rabies immune globulin [human]), a...

GRF : 7.65 (-0.65%)
GRFS : 18.53 (-0.86%)
GRFS vs. ZTS: Which Stock Should Value Investors Buy Now?

GRFS vs. ZTS: Which Stock Is the Better Value Option?

GRFS : 18.53 (-0.86%)
ZTS : 160.38 (-0.68%)
People Who Have Recovered from COVID-19 Can Now Donate their Convalescent Plasma in select Grifols U.S. Plasma Donor Centers

Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company with a track record of more than 100 years and a recognized leader in the development and production of plasma-derived medicines,...

GRF : 7.65 (-0.65%)
GRFS : 18.53 (-0.86%)
Myasthenia Gravis Market 2017-2030 Global Review and Outlook | Shire, Roche Holding AG, CSL Behring, Grifols, S.A.

Myasthenia Gravis Market Report provides the detailed overview of the disease and in depth understanding of historical and forecasted epidemiology. It highlights the existing treatment patterns, potential...

RHHBY : 40.8200 (-2.18%)
TKPYY : 16.5900 (-0.90%)
VRX.TO : 30.80 (-3.33%)
GRFS : 18.53 (-0.86%)
ALXN : 122.11 (-1.39%)
AVDL : 7.18 (-3.88%)
BAX : 76.07 (+0.13%)
NVS : 90.83 (+1.19%)
GRFS vs. ZTS: Which Stock Should Value Investors Buy Now?

GRFS vs. ZTS: Which Stock Is the Better Value Option?

GRFS : 18.53 (-0.86%)
ZTS : 160.38 (-0.68%)
Grifols 2019 Annual Report on Form 20-F Filed With the SEC on April 6, 2020

Grifols, S.A. ("Grifols") (MCE: GRF) (MCE: GRF.P) (NASDAQ: GRFS) announced that it has filed its 2019 Annual Report on Form 20-F with the United States Securities and Exchange Commission ("SEC") on April...

GRF : 7.65 (-0.65%)
GRFS : 18.53 (-0.86%)
How Grifols (GRFS) Stock Stands Out in a Strong Industry

Grifols (GRFS) has seen solid earnings estimate revision activity over the past two months, and belongs to a strong industry as well.

GRFS : 18.53 (-0.86%)

Van Meerten Stock Picks

5 Great Small Caps
Summary 100% technical buy signals.
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar